Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Jan;35(1):5–9. doi: 10.1128/aac.35.1.5

Rifampin resistance of Legionella pneumophila is not increased during therapy for experimental Legionnaires disease: study of rifampin resistance using a guinea pig model of Legionnaires disease.

P H Edelstein 1
PMCID: PMC244932  PMID: 2014980

Abstract

Isolates of Legionella pneumophila serogroup 1, obtained from guinea pigs with experimentally induced Legionnaires disease, were tested for rifampin resistance. Thirteen isolates were from animals treated with rifampin alone, four isolates were from animals treated with saline, and three isolates each were from animals treated with erythromycin or erythromycin plus rifampin; all of these isolates were derived from the same parent strain, F889. Most of the isolates were obtained from rifampin-treated animals that survived infection but had persistence of bacteria in their lungs at necropsy. No differences in rifampin agar dilution MICs were detected for the 23 isolates and parent strain that were tested. None of the 13 isolates from animals treated with rifampin alone had a high number of resistant organisms detected by using a rifampin gradient plate assay. Thirteen isolates plus the parent strain were tested by using a quantitative method of determining resistance frequency. Considerable heterogeneity among isolates was observed, but there was no evidence of increased resistance for any treatment group. The range of rifampin resistance frequencies was 10(-7) to 10(-8). No evidence for rifampin-induced resistance of L. pneumophila was found in this study.

Full text

PDF
5

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Band J. D., Chamberland M. E., Platt T., Weaver R. E., Thornsberry C., Fraser D. W. Trends in meningococcal disease in the United States, 1975-1980. J Infect Dis. 1983 Oct;148(4):754–758. doi: 10.1093/infdis/148.4.754. [DOI] [PubMed] [Google Scholar]
  2. Baronti A., Lukinovich N. A pilot trial of rifampicin in tuberculosis. Tubercle. 1968 Jun;49(2):180–186. doi: 10.1016/0041-3879(68)90020-2. [DOI] [PubMed] [Google Scholar]
  3. Beaty H. N. Rifampin and minocycline in meningococcal disease. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S451–S458. doi: 10.1093/clinids/5.supplement_3.s451. [DOI] [PubMed] [Google Scholar]
  4. David H. L. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 1970 Nov;20(5):810–814. doi: 10.1128/am.20.5.810-814.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dowling J. N., McDevitt D. A., Pasculle A. W. Disk diffusion antimicrobial susceptibility testing of members of the family Legionellaceae including erythromycin-resistant variants of Legionella micdadei. J Clin Microbiol. 1984 Jun;19(6):723–729. doi: 10.1128/jcm.19.6.723-729.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Edelstein P. H., Calarco K., Yasui V. K. Antimicrobial therapy of experimentally induced Legionnaires' disease in guinea pigs. Am Rev Respir Dis. 1984 Nov;130(5):849–856. doi: 10.1164/arrd.1984.130.5.849. [DOI] [PubMed] [Google Scholar]
  7. Edelstein P. H., Edelstein M. A. WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages. Antimicrob Agents Chemother. 1989 Dec;33(12):2132–2136. doi: 10.1128/aac.33.12.2132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gibson D. H., Fitzgeorge R. B., Baskerville A. Antibiotic therapy of experimental airborne Legionnaires' disease. J Infect. 1983 Nov;7(3):210–217. doi: 10.1016/s0163-4453(83)97034-2. [DOI] [PubMed] [Google Scholar]
  9. Havlichek D., Pohlod D., Saravolatz L. Comparison of ciprofloxacin and rifampicin in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother. 1987 Dec;20(6):875–881. doi: 10.1093/jac/20.6.875. [DOI] [PubMed] [Google Scholar]
  10. Jones R. N., Barry A. L. The antimicrobial activity of A-56268 (TE-031) and roxithromycin (RU965) against Legionella using broth microdilution method. J Antimicrob Chemother. 1987 Jun;19(6):841–842. doi: 10.1093/jac/19.6.841. [DOI] [PubMed] [Google Scholar]
  11. Luria S. E., Delbrück M. Mutations of Bacteria from Virus Sensitivity to Virus Resistance. Genetics. 1943 Nov;28(6):491–511. doi: 10.1093/genetics/28.6.491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mandell G. L., Moorman D. R. Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance. Antimicrob Agents Chemother. 1980 Apr;17(4):658–662. doi: 10.1128/aac.17.4.658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. McCabe W. R., Lorian V. Comparison of the antibacterial activity of rifampicin and other antibiotics. Am J Med Sci. 1968 Oct;256(4):255–265. doi: 10.1097/00000441-196810000-00007. [DOI] [PubMed] [Google Scholar]
  14. Meenhorst P. L., van der Meer J. W., Borst J. Sporadic cases of Legionnaires' disease in the Netherlands. Ann Intern Med. 1979 Apr;90(4):529–532. doi: 10.7326/0003-4819-90-4-529. [DOI] [PubMed] [Google Scholar]
  15. Mercatello A., Frappaz D., Robert D., Bornstein N., Fleurette F. Failure of erythromycin/rifampicin treatment of legionella pneumonia. J Infect. 1985 May;10(3):282–283. doi: 10.1016/s0163-4453(85)92838-5. [DOI] [PubMed] [Google Scholar]
  16. Moffie B. G., Mouton R. P. Sensitivity and resistance of Legionella pneumophila to some antibiotics and combinations of antibiotics. J Antimicrob Chemother. 1988 Oct;22(4):457–462. doi: 10.1093/jac/22.4.457. [DOI] [PubMed] [Google Scholar]
  17. Moorman D. R., Mandell G. L. Characteristics of rifampin-resistant variants obtained from clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 1981 Dec;20(6):709–713. doi: 10.1128/aac.20.6.709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Murphy T. V., McCracken G. H., Jr, Zweighaft T. C., Hansen E. J. Emergence of rifampin-resistant Haemophilus influenzae after prophylaxis. J Pediatr. 1981 Sep;99(3):406–409. doi: 10.1016/s0022-3476(81)80328-9. [DOI] [PubMed] [Google Scholar]
  19. Pasculle A. W., Dowling J. N., Frola F. N., McDevitt D. A., Levi M. A. Antimicrobial therapy of experimental Legionella micdadei pneumonia in guinea pigs. Antimicrob Agents Chemother. 1985 Dec;28(6):730–734. doi: 10.1128/aac.28.6.730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rudin J. E., Evans T. L., Wing E. J. Failure of erythromycin in treatment of Legionella micdadei pneumonia. Am J Med. 1984 Feb;76(2):318–320. doi: 10.1016/0002-9343(84)90793-9. [DOI] [PubMed] [Google Scholar]
  21. Saito A., Sawatari K., Fukuda Y., Nagasawa M., Koga H., Tomonaga A., Nakazato H., Fujita K., Shigeno Y., Suzuyama Y. Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob Agents Chemother. 1985 Jul;28(1):15–20. doi: 10.1128/aac.28.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Thornsberry C., Hill B. C., Swenson J. M., McDougal L. K. Rifampin: spectrum of antibacterial activity. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S412–S417. doi: 10.1093/clinids/5.supplement_3.s412. [DOI] [PubMed] [Google Scholar]
  23. Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S407–S411. doi: 10.1093/clinids/5.supplement_3.s407. [DOI] [PubMed] [Google Scholar]
  24. Wheat L. J., Kohler R. B., Luft F. C., White A. Long-term studies of the effect of rifampin on nasal carriage of coagulase-positive staphylococci. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S459–S462. doi: 10.1093/clinids/5.supplement_3.s459. [DOI] [PubMed] [Google Scholar]
  25. Zak O., Scheld W. M., Sande M. A. Rifampin in experimental endocarditis due to Staphylococcus aureus in rabbits. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S481–S490. doi: 10.1093/clinids/5.supplement_3.s481. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES